ATE496893T1 - Isochinolinonderivate und deren verwendung als medikamente - Google Patents
Isochinolinonderivate und deren verwendung als medikamenteInfo
- Publication number
- ATE496893T1 ATE496893T1 AT03814127T AT03814127T ATE496893T1 AT E496893 T1 ATE496893 T1 AT E496893T1 AT 03814127 T AT03814127 T AT 03814127T AT 03814127 T AT03814127 T AT 03814127T AT E496893 T1 ATE496893 T1 AT E496893T1
- Authority
- AT
- Austria
- Prior art keywords
- sup
- medications
- isoquinolinone derivatives
- compounds
- disclosed
- Prior art date
Links
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- VDBNYAPERZTOOF-UHFFFAOYSA-N isoquinolin-1(2H)-one Chemical class C1=CC=C2C(=O)NC=CC2=C1 VDBNYAPERZTOOF-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 108020005497 Nuclear hormone receptor Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 102000006255 nuclear receptors Human genes 0.000 abstract 1
- 108020004017 nuclear receptors Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43585102P | 2002-12-20 | 2002-12-20 | |
| PCT/US2003/040275 WO2004058717A1 (en) | 2002-12-20 | 2003-12-17 | Isoquinolinone derivatives and their use as therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE496893T1 true ATE496893T1 (de) | 2011-02-15 |
Family
ID=32682285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03814127T ATE496893T1 (de) | 2002-12-20 | 2003-12-17 | Isochinolinonderivate und deren verwendung als medikamente |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US7265131B2 (de) |
| EP (1) | EP1572660B1 (de) |
| AT (1) | ATE496893T1 (de) |
| AU (1) | AU2003301020A1 (de) |
| DE (1) | DE60335911D1 (de) |
| ES (1) | ES2361924T3 (de) |
| TW (1) | TW200418801A (de) |
| WO (1) | WO2004058717A1 (de) |
Families Citing this family (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2584485C (en) * | 2004-10-20 | 2013-12-31 | Resverlogix Corp. | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases |
| EP1831225A2 (de) | 2004-11-19 | 2007-09-12 | The Regents of the University of California | Entzündungshemmende pyrazolopyrimidine |
| EA200870409A1 (ru) | 2006-04-04 | 2009-04-28 | Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния | Антагонисты киназы pi3 |
| EP2098515B1 (de) | 2006-11-30 | 2012-02-08 | Kowa Company, Ltd. | Substituierte carbinolverbindungen |
| US9604931B2 (en) | 2007-01-22 | 2017-03-28 | Gtx, Inc. | Nuclear receptor binding agents |
| WO2008091555A2 (en) | 2007-01-22 | 2008-07-31 | Gtx, Inc. | Nuclear receptor binding agents |
| US9623021B2 (en) | 2007-01-22 | 2017-04-18 | Gtx, Inc. | Nuclear receptor binding agents |
| DK2118074T3 (en) * | 2007-02-01 | 2014-03-10 | Resverlogix Corp | Compounds for the prevention and treatment of cardiovascular diseases |
| CL2008001903A1 (es) * | 2007-06-29 | 2009-03-06 | Harvard College | Linea celular que comprende una o mas celulas que expresan en forma estable una secuencia de acidos nucleicos que codifica un promotor regulador de esteroles y que esta unida en forma operativa a una secuencia de acidos nucleicos que codifica una etiqueta detectable; y metodo para determinar si un compuesto reduce el colesterol. |
| GB2467670B (en) | 2007-10-04 | 2012-08-01 | Intellikine Inc | Chemical entities and therapeutic uses thereof |
| CA2711558C (en) | 2008-01-04 | 2016-12-13 | Intellikine, Inc. | Phosphatidyl inositol-3 kinase inhibiting compounds |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| EP2248811B1 (de) | 2008-02-29 | 2012-11-14 | Kowa Company, Ltd. | 2-oxochromen-derivat |
| US8993580B2 (en) | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
| JP5547099B2 (ja) | 2008-03-14 | 2014-07-09 | インテリカイン， エルエルシー | キナーゼ阻害剤および使用方法 |
| JP5511080B2 (ja) | 2008-03-31 | 2014-06-04 | 興和株式会社 | １，３−ジヒドロイソベンゾフラン誘導体 |
| JP5371118B2 (ja) | 2008-04-30 | 2013-12-18 | 興和株式会社 | キノリン化合物 |
| CN102088853A (zh) * | 2008-05-12 | 2011-06-08 | 安内斯蒂克斯公司 | 改善学习和记忆的化合物 |
| CN102105452A (zh) | 2008-05-29 | 2011-06-22 | 兴和株式会社 | 具有环状连接基的取代甲醇化合物 |
| KR101629356B1 (ko) | 2008-06-26 | 2016-06-13 | 리스버로직스 코퍼레이션 | 퀴나졸리논 유도체의 제조방법 |
| AU2009268611B2 (en) | 2008-07-08 | 2015-04-09 | Intellikine, Llc | Kinase inhibitors and methods of use |
| WO2010006072A2 (en) | 2008-07-08 | 2010-01-14 | The Regents Of The University Of California | Mtor modulators and uses thereof |
| JP5731978B2 (ja) | 2008-09-26 | 2015-06-10 | インテリカイン， エルエルシー | 複素環キナーゼ阻害剤 |
| CA2740746A1 (en) * | 2008-10-14 | 2010-04-22 | Ning Xi | Compounds comprising a spiro-ring and and methods of use |
| CA2740885C (en) | 2008-10-16 | 2018-04-03 | The Regents Of The University Of California | Fused ring heteroaryl kinase inhibitors |
| US8476282B2 (en) | 2008-11-03 | 2013-07-02 | Intellikine Llc | Benzoxazole kinase inhibitors and methods of use |
| NZ594332A (en) * | 2009-01-08 | 2013-09-27 | Resverlogix Corp | Compounds for the prevention and treatment of cardiovascular disease |
| KR101709492B1 (ko) | 2009-03-18 | 2017-02-23 | 리스버로직스 코퍼레이션 | 신규한 소염제 |
| EP2408300B1 (de) * | 2009-03-21 | 2016-05-11 | Sunshine Lake Pharma Co., Ltd. | Aminoesterderivate, salze daraus und verfahren zu ihrer verwendung |
| US9757368B2 (en) | 2009-04-22 | 2017-09-12 | Resverlogix Corp. | Anti-inflammatory agents |
| EA201171167A1 (ru) | 2009-04-29 | 2012-06-29 | Кова Компани, Лтд. | Карбинольное соединение, содержащее гетероциклический линкер |
| EP2427195B1 (de) | 2009-05-07 | 2019-05-01 | Intellikine, LLC | Heterocyclische verbindungen und ihre verwendung |
| WO2011047384A2 (en) | 2009-10-16 | 2011-04-21 | The Regents Of The University Of California | Methods of inhibiting ire1 |
| AU2011255218B2 (en) | 2010-05-21 | 2015-03-12 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
| JP2013545749A (ja) | 2010-11-10 | 2013-12-26 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | 複素環化合物及びその使用 |
| AU2012205669B2 (en) | 2011-01-10 | 2015-08-20 | Infinity Pharmaceuticals Inc. | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
| JP6130305B2 (ja) | 2011-02-23 | 2017-05-17 | インテリカイン， エルエルシー | キナーゼ阻害剤の組み合わせおよびそれらの使用 |
| US9056877B2 (en) | 2011-07-19 | 2015-06-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| JP6027610B2 (ja) | 2011-07-19 | 2016-11-16 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | 複素環式化合物及びその使用 |
| EP2751093A1 (de) | 2011-08-29 | 2014-07-09 | Infinity Pharmaceuticals, Inc. | Heterocyclische verbindungen und ihre verwendung |
| MX370814B (es) | 2011-09-02 | 2020-01-08 | Univ California | Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas. |
| RU2640115C2 (ru) | 2011-11-01 | 2017-12-26 | Ресверлоджикс Корп. | Фармацевтические композиции замещенных хиназолинонов |
| EP3441390A1 (de) | 2012-03-02 | 2019-02-13 | Ralexar Therapeutics, Inc. | Leber-x-rezeptor (lxr)-modulatoren zur behandlung von hautkrankheiten, -störungen und -leiden |
| WO2013132253A1 (en) | 2012-03-07 | 2013-09-12 | Institute Of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| CN102875466A (zh) * | 2012-04-23 | 2013-01-16 | 中国药科大学 | 异喹啉酮衍生物,其制备方法及其医药用途 |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| MX2015003874A (es) | 2012-09-26 | 2015-12-16 | Univ California | Modulacion de ire1. |
| KR102229478B1 (ko) | 2012-11-01 | 2021-03-18 | 인피니티 파마슈티칼스, 인코포레이티드 | Pi3 키나아제 동형단백질 조절인자를 사용하는 암의 치료 |
| US9073878B2 (en) | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
| WO2014080291A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Biaryl derivatives as bromodomain inhibitors |
| US9271978B2 (en) | 2012-12-21 | 2016-03-01 | Zenith Epigenetics Corp. | Heterocyclic compounds as bromodomain inhibitors |
| US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
| AU2014315280B2 (en) | 2013-09-04 | 2019-01-24 | Ellora Therapeutics, Inc. | Liver X receptor (LXR) modulators |
| SG11201601644RA (en) | 2013-09-04 | 2016-04-28 | Alexar Therapeutics Inc | Liver x receptor (lxr) modulators |
| EP3044221B1 (de) | 2013-09-11 | 2018-02-21 | Institute of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituierte isochinolin-1-on-verbindungen und deren therapeutische anwendung |
| US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| PE20160685A1 (es) | 2013-10-04 | 2016-07-23 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos y usos de los mismos |
| EP3091970B1 (de) | 2014-01-10 | 2020-10-28 | Rgenix, Inc. | Lxr-agonisten und verwendungen davon |
| SG10201808053XA (en) | 2014-03-19 | 2018-10-30 | Infinity Pharmaceuticals Inc | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
| US20150320755A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
| US10111885B2 (en) | 2015-03-13 | 2018-10-30 | Resverlogix Corp. | Compositions and therapeutic methods for the treatment of complement-associated diseases |
| US10160761B2 (en) | 2015-09-14 | 2018-12-25 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same |
| US11648220B2 (en) | 2016-01-11 | 2023-05-16 | The Rockefeller University | Methods for the treatment of myeloid derived suppressor cells related disorders |
| WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
| US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| MX391135B (es) | 2016-06-24 | 2025-03-21 | Infinity Pharmaceuticals Inc | Terapias de combinacion. |
| AU2018373028A1 (en) | 2017-11-21 | 2020-04-30 | Inspirna, Inc. | Polymorphs and uses thereof |
| US20220193250A1 (en) | 2018-08-02 | 2022-06-23 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| JP7611825B2 (ja) | 2018-08-02 | 2025-01-10 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| IL283592B2 (en) | 2018-12-17 | 2025-08-01 | Vertex Pharma | Inhibitors of apol1 and methods of using same |
| EP4073025B1 (de) | 2019-12-13 | 2024-03-27 | Inspirna, Inc. | Metallsalze und verwendungen davon |
| EP4097083A1 (de) | 2020-01-29 | 2022-12-07 | Vertex Pharmaceuticals Incorporated | Inhibitoren von apol1 und verfahren zur verwendung davon |
| US12624120B2 (en) | 2020-01-31 | 2026-05-12 | Dyne Therapeutics, Inc. | Anti-transferrin receptor (TfR) antibody and uses thereof |
| EP4165036A1 (de) | 2020-06-12 | 2023-04-19 | Vertex Pharmaceuticals Incorporated | Feste formen von apol1-inhibitor und verwendung davon |
| CN116157393A (zh) | 2020-06-12 | 2023-05-23 | 弗特克斯药品有限公司 | Apol1的抑制剂及其用途 |
| WO2022013684A1 (en) | 2020-07-11 | 2022-01-20 | Pfizer Inc. | Antiviral heteroaryl ketone derivatives |
| CR20230120A (es) | 2020-08-07 | 2023-09-01 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
| US12324802B2 (en) | 2020-11-18 | 2025-06-10 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| CN117980006A (zh) | 2021-07-09 | 2024-05-03 | 达因疗法公司 | 用于治疗肌养蛋白病的肌肉靶向复合物和制剂 |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| CN116693456A (zh) * | 2022-02-28 | 2023-09-05 | 复旦大学 | 异喹啉酮类化合物及其制备方法和应用 |
| KR20250004770A (ko) | 2022-04-15 | 2025-01-08 | 다인 세라퓨틱스, 인크. | 근긴장성 이영양증을 치료하기 위한 근육 표적화 복합체 및 제제 |
| CN117486753B (zh) * | 2023-10-13 | 2026-04-03 | 天津科技大学 | 一类具有驱蚊作用的含氟苯甲酰二乙胺类化合物、方法及在驱蚊剂中的应用 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3452027A (en) * | 1967-07-03 | 1969-06-24 | American Home Prod | 2-hydroxyalkylisocarbostyrils |
| JPS5424882A (en) * | 1977-07-22 | 1979-02-24 | Yamanouchi Pharmaceut Co Ltd | Novel heterocyclic compounds and their preparation |
| US5115626A (en) * | 1988-09-30 | 1992-05-26 | Rapak, Inc. | Apparatus for filling flexible plastic bags carried in a continuous web and supplies therefore |
| US4969310A (en) * | 1989-05-12 | 1990-11-13 | Automated Packaging Systems, Inc. | Packaging machine and method |
| CA2028538A1 (en) | 1989-10-27 | 1991-04-28 | Hideaki Natsugari | 4-substituted isoquinolone derivatives, their production and use |
| US5187917A (en) * | 1990-10-29 | 1993-02-23 | Cvp Systems, Inc. | Automatic packaging apparatus and method and flexible pouch therefor |
| US5334600A (en) * | 1991-07-30 | 1994-08-02 | Ciba-Geigy Corporation | Isoquinolyl substituted hydroxylamine derivatives |
| US5350761A (en) * | 1991-07-30 | 1994-09-27 | Ciba-Geigy Corporation | Indolyl substituted hydroxylamine derivatives |
| US5260316A (en) * | 1991-07-30 | 1993-11-09 | Ciba-Geigy Corporation | Isoquinolyl substituted hydroxylamine derivatives |
| ES2111059T3 (es) | 1991-07-30 | 1998-03-01 | Ciba Geigy Ag | Derivados de hidroxilamina substituidos con heteroarilo como inhibidores de lipoxigenasa. |
| JP3141051B2 (ja) | 1992-10-09 | 2001-03-05 | 日清製粉株式会社 | 抗動脈硬化剤 |
| SE501545C2 (sv) * | 1993-05-05 | 1995-03-13 | Jan Jostler | Bana för förpackningsämnen samt sätt att öppna och fylla förpackningsfickor i banan |
| US5607898A (en) * | 1993-08-02 | 1997-03-04 | Idemitsu Kosan Company, Ltd. | Pyrazole derivatives |
| US5607967A (en) * | 1994-10-27 | 1997-03-04 | Merck & Co., Inc. | Treatment of alzheimer's disease with 5-(tetradecyloxy)-2-furan carboxylic acid |
| US5642599A (en) * | 1994-11-14 | 1997-07-01 | Tisma Machinery Corporation | Automatic packaging machine for boxes with paper end liners |
| WO1997043263A1 (en) | 1995-11-17 | 1997-11-20 | Toray Industries, Inc. | PROCESS FOR PRODUCING 4a-ARYLDECAHYDROISOQUINOLINE DERIVATIVES |
| FR2728900B1 (fr) * | 1994-12-29 | 1997-01-31 | Synthelabo | Derives de 3-phenylisoquinolein-1(2h)-one, leur preparation et leur application en therapeutique |
| US5747661A (en) * | 1995-01-13 | 1998-05-05 | Howard Hughes Medical Institute | Retinoid-inducible response elements |
| US5945380A (en) * | 1995-05-26 | 1999-08-31 | Bayer Aktiengesellschaft | Pyridyl-thiazoles and their use to protect plants against infections by micro-organisms |
| EP0845460A4 (de) | 1996-05-15 | 1998-09-02 | Toray Industries | VERFAHREN ZUR HERSTELLUNG VON 4a-ARYLDECAHYDROISOCHINOLIN-DERIVATEN |
| FR2750427B1 (fr) | 1996-06-28 | 1998-08-07 | Synthelabo | Derives de 1-oxo-1, 2-dihydroisoquinoleine-4-propanamide, leur preparation et leur application en therapeutique |
| US5743070A (en) * | 1996-08-16 | 1998-04-28 | Automated Packaging Systems, Inc. | Packaging machine, material and method |
| TR199901343T2 (xx) | 1996-12-23 | 1999-09-21 | Elan Pharmaceuticals, Inc. | Sikloalkil, laktam, lakton ve ilgili bile�ikler, bunlar� i�eren farmas�tik bile�imler ve b�yle bile�ikler kullan�larak �-amiloid peptidinin sal�nmas�n� ve/veya sentezini inhibe etmek i�in y�ntemler. |
| AU5928898A (en) * | 1997-01-24 | 1998-08-18 | Regents Of The University Of California, The | Use of fxr, pparalpha and lxralpha activators to restore barrier function, promote epidermal differentiation and inhibit proliferation |
| CA2291630A1 (en) | 1997-05-30 | 1998-12-03 | Tetsutaro Niizato | Nitrogen-containing heterocyclic compounds and therapeutic agents for hyperlipidemia comprising the same |
| FR2772760B1 (fr) | 1997-12-22 | 2000-02-04 | Synthelabo | Derives de 3-oxazol-5-yl-1-oxo-1,2-dihydroisoquinoleine-4- propanamide, leur preparation et leur application en therapeutique |
| EP1115853A2 (de) | 1998-09-23 | 2001-07-18 | Ludmila Solomin | "in vivo" analyse von ligand-activierten kernrezeptoren i |
| ES2326850T3 (es) | 1998-12-23 | 2009-10-20 | Glaxo Group Limited | Ensayos para ligandos de receptores nucleares. |
| US6316503B1 (en) | 1999-03-15 | 2001-11-13 | Tularik Inc. | LXR modulators |
| WO2000057915A1 (en) | 1999-03-26 | 2000-10-05 | City Of Hope | Method of affecting cholesterol catabolism using nuclear bile acid receptor |
| BR0010197A (pt) | 1999-04-30 | 2002-07-16 | Arch Dev Corp | Derivados de esteróides |
| ATE422545T1 (de) | 1999-06-18 | 2009-02-15 | Cv Therapeutics Inc | Regulierung mittels atp binding cassette transporter proteins abc1 |
| WO2001015676A2 (en) | 1999-09-01 | 2001-03-08 | University Of British Columbia | Compositions and methods for modulating hdl cholesterol and triglyceride levels |
| WO2001060818A1 (en) | 2000-02-14 | 2001-08-23 | Tularik Inc. | Lxr modulators |
| US6673543B2 (en) | 2000-04-05 | 2004-01-06 | Tularik, Inc. | Solid phase synthesis of LXR ligands |
| WO2001082917A2 (en) | 2000-05-03 | 2001-11-08 | Tularik Inc. | Treatment of hypertriglyceridemia and other conditions using lxr modulators |
| GB0019290D0 (en) | 2000-08-04 | 2000-09-27 | Symphar Sa | Methods for inducing apolipoprotein E secretion |
| PE20021002A1 (es) | 2001-02-02 | 2002-12-06 | Takeda Chemical Industries Ltd | Compuestos heterociclicos condensados |
| US6924311B2 (en) | 2001-10-17 | 2005-08-02 | X-Ceptor Therapeutics, Inc. | Methods for affecting various diseases utilizing LXR compounds |
| EP1521746B1 (de) | 2002-03-07 | 2011-04-27 | X-Ceptor Therapeutics, Inc. | Chinazolinon modulatoren von nukleinrezeptoren |
-
2003
- 2003-12-17 EP EP03814127A patent/EP1572660B1/de not_active Expired - Lifetime
- 2003-12-17 US US10/738,964 patent/US7265131B2/en not_active Expired - Lifetime
- 2003-12-17 ES ES03814127T patent/ES2361924T3/es not_active Expired - Lifetime
- 2003-12-17 AT AT03814127T patent/ATE496893T1/de not_active IP Right Cessation
- 2003-12-17 DE DE60335911T patent/DE60335911D1/de not_active Expired - Lifetime
- 2003-12-17 AU AU2003301020A patent/AU2003301020A1/en not_active Abandoned
- 2003-12-17 WO PCT/US2003/040275 patent/WO2004058717A1/en not_active Ceased
- 2003-12-22 TW TW092136405A patent/TW200418801A/zh unknown
-
2007
- 2007-07-27 US US11/829,324 patent/US20080132521A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2361924T3 (es) | 2011-06-24 |
| WO2004058717A1 (en) | 2004-07-15 |
| US20080132521A1 (en) | 2008-06-05 |
| US7265131B2 (en) | 2007-09-04 |
| AU2003301020A1 (en) | 2004-07-22 |
| TW200418801A (en) | 2004-10-01 |
| AU2003301020A8 (en) | 2004-07-22 |
| WO2004058717A8 (en) | 2004-08-19 |
| EP1572660B1 (de) | 2011-01-26 |
| EP1572660A1 (de) | 2005-09-14 |
| DE60335911D1 (de) | 2011-03-10 |
| US20040204447A1 (en) | 2004-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60335911D1 (de) | Isochinolinonderivate und deren verwendung als medikamente | |
| ATE327977T1 (de) | Tetrahydrochinolin-derivate als crth2 antagonisten | |
| ATE547416T1 (de) | Pyrazolylbenzothiazolderivate und deren verwendung als therapeutische mittel | |
| DE60221969D1 (de) | Durch piperidine-enthaltende gruppen substituierte chinoline und deren stickstoff-enthaltende derivate und ihre verwendung als antibakterielle wirkstoffe | |
| ATE532772T1 (de) | Piperazinderivate und deren verwendung als therapeutische mittel | |
| ATE555789T1 (de) | Pyridazinderivate und deren verwendung als therapeutische mittel | |
| MY137535A (en) | New pyrrolidinium derivatives | |
| DE502004006507D1 (de) | Imidazopyridazinon- und imidazopyridonderivate, deren herstellung und deren verwendung als arzneimittel | |
| DE60118975D1 (de) | Tetrahydropyridinderivate, deren herstellung und deren verwendung als inhibitoren der zellproliferation | |
| ATE311363T1 (de) | Sulfohydroxamsäure and sulfohydroxamate und ihre verwendung als mek-inhibitoren | |
| DE60124761D1 (de) | Chinoline und deren in der 4-stellung durch eine piperazinhaltige gruppe substituierte nitrogenierte derivate und deren verwendung als antibakterielle mittel | |
| ATE556056T1 (de) | Pyridylderivate und deren verwendung als therapeutische mittel | |
| DE69431069D1 (de) | Cyclische amidderivate als neurokinin a antagonisten | |
| DE60305484D1 (de) | Verbindungen und deren verwendung als 5-ht inhibitore | |
| DE60325493D1 (de) | Substituierte 1,4-dipiperidin-4-yl-piperazinderivate und deren verwendung als neurokininantagonisten | |
| DE602004012758D1 (de) | Chinoxalinderivate als inhibitoren der neutrophilelastase und deren verwendung | |
| ATE495187T1 (de) | Dalda-analoge und ihre verwendung | |
| SE0302573D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
| ATE355265T1 (de) | Biphenylcarboxamidderivate und ihre verwendung als p38 kinase inhibitoren | |
| DE602004031410D1 (de) | Inden derivate als pharmazeutika | |
| DE60108626D1 (de) | Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b] pyridinen als cyclin-abhängige kinase-hemmer | |
| ATE429421T1 (de) | Arylindenopyridin- und arylindenopyrimidinverbindungen und ihre verwendung als adenosin-a2a-rezeptor antagonisten | |
| SE0302570D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
| SE0300105D0 (sv) | Diarylmethylidene piperdine derivatives, preparations thereof and uses thereof | |
| DE69803383D1 (de) | Selektive inhibitoren des faktors x, eine azepinonstruktur enthaltend |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |